Create Medicines

Executive Summary

Create Medicines is a preclinical-stage biotechnology company pioneering an in vivo immune cell reprogramming platform using RNA and lipid nanoparticle (LNP) delivery to generate off-the-shelf CAR therapies. By directly programming T cells, NK cells, and myeloid cells within patients, the platform aims to overcome the manufacturing and cost barriers of ex vivo cell therapy while targeting a broad range of diseases including cancer, autoimmunity, and fibrosis. Founded in 2021 and based in Boston, the company has rapidly advanced to Phase 3 development, though no specific pipeline details are public. With a versatile platform capable of addressing multiple therapeutic areas, Create Medicines has the potential to transform cell therapy by enabling scalable, repeatable, and accessible treatments. The company's approach addresses key limitations of current CAR-T therapies, such as complex manufacturing, high costs, and limited patient access. If successful, this platform could expand the use of immune cell programming to larger patient populations and new disease indications, representing a significant leap forward in cell and gene therapy.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 clinical data readout for lead CAR candidate in oncology55% success
• Q1 2027IND filing and first-in-human data for autoimmune indication60% success
• Q2 2026Announcement of strategic partnership for fibrosis program70% success